Drug intelligence / Profile preview

[177Lu]Lu-EVS459

Development stage: Unknown
Lead developer: Novartis
Modality: Implantable Devices → Device-based Delivery → Drug Delivery Systems
Administration: Intravenous

Overview

[177Lu]Lu-EVS459 is a therapeutic radiopharmaceutical in Phase 1 clinical development by Novartis Pharmaceuticals. It contains lutetium-177, a radioactive isotope, conjugated to a targeting molecule (presumably EVS459). The drug is designed to deliver targeted radiation therapy directly to specific cancer cells, minimizing damage to healthy tissues. It is administered intravenously and is being investigated for the treatment of advanced high-grade serous ovarian cancer and locally advanced unresectable or metastatic non-squamous non-small cell lung carcinoma. It is used in conjunction with [68Ga]Ga-EVS459, an imaging agent, to identify potential treatment candidates.

Targets

FOLR1 (FRα)

Beyond the preview

Go deeper on [177Lu]Lu-EVS459.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on [177Lu]Lu-EVS459.

Explore the full profile